Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy
Abstract Adoptive immunotherapy, in which tumor-reactive T cells are prepared in vitro for adoptive transfer to the patient, can induce an objective clinical response in specific types of cancer. In particular, chimeric antigen receptor (CAR)-redirected T-cell therapy has shown robust responses in h...
Main Authors: | Yusuke Ito, Satoshi Inoue, Yuki Kagoya |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-03-01
|
Series: | Inflammation and Regeneration |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41232-024-00324-7 |
Similar Items
-
Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions
by: Peng Zhang, et al.
Published: (2022-07-01) -
Therapeutic Applications: Natural Killer Cells
by: Preeti Sharma, et al.
Published: (2018-02-01) -
Beyond CD19: Opportunities for future development of targeted immunotherapy in pediatric relapsed-refractory acute leukemia
by: Haneen eShalabi, et al.
Published: (2015-10-01) -
Adoptive Immunotherapy for Hematological Malignancies Using T Cells Gene-Modified to Express Tumor Antigen-Specific Receptors
by: Hiroshi Fujiwara
Published: (2014-12-01) -
Bioinformatic Description of Immunotherapy Targets for Pediatric T-Cell Leukemia and the Impact of Normal Gene Sets Used for Comparison
by: Rimas J Orentas, et al.
Published: (2014-06-01)